Literature DB >> 11770056

Latent inhibition, but not prepulse inhibition, is reduced during withdrawal from an escalating dosage schedule of amphetamine.

C A Murphy1, M Fend, H Russig, J Feldon.   

Abstract

The enhanced locomotor and stereotypic responses of the rat to repeated amphetamine (AMPH) administration are considered to be an animal model of positive schizophrenic symptoms. In contrast, behaviors observed during withdrawal from repeated AMPH are believed to model depression or anxiety. In the present study, the authors tested whether AMPH withdrawal might also elicit behaviors consistent with animal models of schizophrenia, specifically, disruptions in latent inhibition (LI) of 2-way active avoidance and prepulse inhibition (PPI) of startle. Rats treated with escalating doses of AMPH (6 days, 1-5 mg/kg ip) or saline were tested for LI and PPI during withdrawal. LI was eliminated by prior AMPH treatment in rats tested at 4, 13, and 28 days of withdrawal. In contrast, PPI did not differ between AMPH and control groups. These results support an interrelationship between repeated-AMPH and LI-disruption, but not PPI-disruption, models of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11770056     DOI: 10.1037//0735-7044.115.6.1247

Source DB:  PubMed          Journal:  Behav Neurosci        ISSN: 0735-7044            Impact factor:   1.912


  17 in total

1.  Psychostimulant-induced plasticity of intrinsic neuronal excitability in ventral subiculum.

Authors:  Donald C Cooper; Shannon J Moore; Nathan P Staff; Nelson Spruston
Journal:  J Neurosci       Date:  2003-10-29       Impact factor: 6.167

2.  Withdrawal from repeated amphetamine administration leads to disruption of prepulse inhibition but not to disruption of latent inhibition.

Authors:  D Peleg-Raibstein; E Sydekum; H Russig; J Feldon
Journal:  J Neural Transm (Vienna)       Date:  2005-12-16       Impact factor: 3.575

3.  Decreased M1 muscarinic receptor density in rat amphetamine model of schizophrenia is normalized by clozapine, but not haloperidol.

Authors:  Adi Malkoff; Abraham Weizman; Illana Gozes; Moshe Rehavi
Journal:  J Neural Transm (Vienna)       Date:  2008-09-20       Impact factor: 3.575

4.  Withdrawal from fixed-dose injection of methamphetamine decreases cerebral levels of 3-methoxy-4-hydroxyphenylglycol and induces the expression of anxiety-related behavior in mice.

Authors:  Nobue Kitanaka; Junichi Kitanaka; Tomohiro Tatsuta; Koh-ichi Tanaka; Kaname Watabe; Nobuyoshi Nishiyama; Yoshio Morita; Motohiko Takemura
Journal:  Neurochem Res       Date:  2010-02-11       Impact factor: 3.996

5.  Baseline prepulse inhibition expression predicts the propensity of developing sensitization to the motor stimulant effects of amphetamine in C57BL/6 mice.

Authors:  Daria Peleg-Raibstein; Jonas Hauser; Luis H Llano Lopez; Joram Feldon; Pascual A Gargiulo; Benjamin K Yee
Journal:  Psychopharmacology (Berl)       Date:  2012-08-17       Impact factor: 4.530

6.  Olanzapine and risperidone disrupt conditioned avoidance responding in phencyclidine-pretreated or amphetamine-pretreated rats by selectively weakening motivational salience of conditioned stimulus.

Authors:  Ming Li; Wei He; Alexa Mead
Journal:  Behav Pharmacol       Date:  2009-02       Impact factor: 2.293

7.  Prepulse inhibition in HIV-1 gp120 transgenic mice after withdrawal from chronic methamphetamine.

Authors:  Brook L Henry; Mark A Geyer; Mahalah R Buell; William Perry; Jared W Young; Arpi Minassian
Journal:  Behav Pharmacol       Date:  2014-02       Impact factor: 2.293

8.  Transient disruption of attentional performance following escalating amphetamine administration in rats.

Authors:  Robyn L Kondrad; Joshua A Burk
Journal:  Psychopharmacology (Berl)       Date:  2004-10       Impact factor: 4.530

Review 9.  Realistic expectations of prepulse inhibition in translational models for schizophrenia research.

Authors:  Neal R Swerdlow; Martin Weber; Ying Qu; Gregory A Light; David L Braff
Journal:  Psychopharmacology (Berl)       Date:  2008-06-21       Impact factor: 4.530

10.  The amphetamine sensitization model of schizophrenia: relevance beyond psychotic symptoms?

Authors:  Daria Peleg-Raibstein; Benjamin K Yee; Joram Feldon; Jonas Hauser
Journal:  Psychopharmacology (Berl)       Date:  2009-03-27       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.